Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer
with an Activating ESR1 Mutation
Contenuto disponibile solo in lingua inglese.